Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07668804 TOO-1007 Geographic Atrophy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07668804, evaluating TOO-1007 in Geographic Atrophy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Denali Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Denali Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
JPRN-jRCT2071260009 Pegcetacoplan Menopausal Vasomotor Symptoms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2071260009, evaluating Pegcetacoplan in Menopausal Vasomotor Symptoms: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07647198 Uterine Fibroids Uterine Fibroids Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07647198, evaluating Uterine Fibroids in Uterine Fibroids: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Neumora Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Neumora Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
NCT07606365 Geographic Atrophy Geographic Atrophy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07606365, evaluating Geographic Atrophy in Geographic Atrophy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Harmony Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Harmony Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
NCT07303296 Lenadogene nolparvovec Leber Hereditary Optic Neuropathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07303296, evaluating Lenadogene nolparvovec in Leber Hereditary Optic Neuropathy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Axsome Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Axsome Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
NCT07568236 Fezolinetant Menopausal Vasomotor Symptoms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07568236, evaluating Fezolinetant in Menopausal Vasomotor Symptoms: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07703280 Osteoarthritis Disease Modification Osteoarthritis Disease Modification Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07703280, evaluating Osteoarthritis Disease Modification in Osteoarthritis Disease Modification: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07695207 Neovascular Age-Related Macular Degeneration Neovascular Age-Related Macular De… Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07695207, evaluating Neovascular Age-Related Macular Degeneration in Neovascular Age-Related Macular Degeneration: trial design, endpoint strategy, sponsor context, benchmark readouts and developme…